PMC:7373848 / 28721-28876 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"550","span":{"begin":19,"end":23},"obj":"Gene"}],"attributes":[{"id":"A550","pred":"tao:has_database_id","subj":"550","obj":"Gene:59272"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"S–COV-2 binding to ACE2 increases STING pathway activation. In most instances, activation occurs during the second phase of illness with immune hyper-respo"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T490","span":{"begin":48,"end":58},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T491","span":{"begin":79,"end":89},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"S–COV-2 binding to ACE2 increases STING pathway activation. In most instances, activation occurs during the second phase of illness with immune hyper-respo"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T901","span":{"begin":19,"end":23},"obj":"G_3;PG_10;PR:000003622"},{"id":"T902","span":{"begin":34,"end":39},"obj":"PR:000016417"},{"id":"T903","span":{"begin":137,"end":143},"obj":"UBERON:0002405"},{"id":"T12955","span":{"begin":19,"end":23},"obj":"G_3;PG_10;PR:000003622"},{"id":"T10255","span":{"begin":34,"end":39},"obj":"PR:000016417"},{"id":"T5446","span":{"begin":137,"end":143},"obj":"UBERON:0002405"}],"text":"S–COV-2 binding to ACE2 increases STING pathway activation. In most instances, activation occurs during the second phase of illness with immune hyper-respo"}